INTRODUCTION: This review summarizes current evidence on insulin efsitora alfa, a novel once-weekly basal insulin developed to simplify therapy in adults with diabetes. Its Fc-fusion molecular design enables a prolonged half-life and a flat pharmacokinetic profile with low variability. Data from the QWINT phase 3 program demonstrate non-inferior glycemic efficacy compared with once-daily basal insulins across type 2 diabetes populations. Reduced injection burden may improve adherence, satisfaction, and diabetes management. AREAS COVERED: This review discusses the molecular structure and pharmacokinetic mechanisms of insulin efsitora alfa, including insulin receptor binding and FcRn-mediated recycling responsible for its extended duration. Efficacy and safety outcomes from pivotal QWINT trials are reviewed, including HbA1c reduction, CGM outcomes, and hypoglycemia risk. Practical considerations such as dosing, titration, and benefits in real-world settings are highlighted. Evidence gaps remain for patients with advanced chronic kidney disease. EXPERT OPINION: Once-weekly insulins such as efsitora and icodec represent major advances in basal therapy. Efsitora's flatter profile may reduce peak-related hypoglycemia, with efficacy comparable to glargine or degludec. Severe hypoglycemia rates are low in type 2 diabetes and more safety data are needed in special populations.
Ramachandran et al. (Tue,) studied this question.